Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh
Vaccination with the Oxford-AstraZeneca COVID-19 vaccine (AZD1222) initially started in the UK and quickly implemented around the Globe, including Bangladesh. Up to date, more than nine million doses administrated to the Bangladeshi public. Herein, we studied the antibody response to the first dose...
Saved in:
Published in | Expert review of vaccines Vol. 20; no. 12; p. 1651 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
02.12.2021
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Vaccination with the Oxford-AstraZeneca COVID-19 vaccine (AZD1222) initially started in the UK and quickly implemented around the Globe, including Bangladesh. Up to date, more than nine million doses administrated to the Bangladeshi public.
Herein, we studied the antibody response to the first dose of AZD1222 in 86 Bangladeshi individuals using in-house ELISA kits. Study subjects were categorized into two groups, convalescent and uninfected, based on prior infection history and SARS-CoV-2 nucleocapsid-IgG profiles.
All the convalescent individuals presented elevated spike-1-IgG compared to 90% of uninfected ones after the first dose. Day >28 post-vaccination, the convalescent group showed six times higher antibody titer than the uninfected ones. The most elevated antibody titers for the former and later group were found at Day 14 and Days >28 post-vaccination, respectively. The spike-1-IgA titer showed a similar pattern as spike-1-IgG, although in a low-titer. In contrast, the IgM titer did not show any significant change in either group.
High antibody titer in the convalescent group, signify the importance of the first dose among the uninfected group. This study advocates the integration of antibody tests in vaccination programs in the healthcare system for maximizing benefit. |
---|---|
AbstractList | Vaccination with the Oxford-AstraZeneca COVID-19 vaccine (AZD1222) initially started in the UK and quickly implemented around the Globe, including Bangladesh. Up to date, more than nine million doses administrated to the Bangladeshi public.
Herein, we studied the antibody response to the first dose of AZD1222 in 86 Bangladeshi individuals using in-house ELISA kits. Study subjects were categorized into two groups, convalescent and uninfected, based on prior infection history and SARS-CoV-2 nucleocapsid-IgG profiles.
All the convalescent individuals presented elevated spike-1-IgG compared to 90% of uninfected ones after the first dose. Day >28 post-vaccination, the convalescent group showed six times higher antibody titer than the uninfected ones. The most elevated antibody titers for the former and later group were found at Day 14 and Days >28 post-vaccination, respectively. The spike-1-IgA titer showed a similar pattern as spike-1-IgG, although in a low-titer. In contrast, the IgM titer did not show any significant change in either group.
High antibody titer in the convalescent group, signify the importance of the first dose among the uninfected group. This study advocates the integration of antibody tests in vaccination programs in the healthcare system for maximizing benefit. |
Author | Jawad, Irfan Ahmed, Md, Firoz Jamiruddin, Raeed Haq, Ahsanul Khandker, Shahad Saif Ahmed, Sohel Rahman, Sabita Rezwana Tomizawa, Kazuhito Mustafi, Mamun Khondoker, Mohib Ullah Ali, Tamanna Mie, Masayasu Haque, Mainul Hossain, Rubel Adnan, Nihad Kobatake, Eiry Kaitsuka, Taku |
Author_xml | – sequence: 1 givenname: Raeed orcidid: 0000-0003-0495-4808 surname: Jamiruddin fullname: Jamiruddin, Raeed organization: Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh – sequence: 2 givenname: Ahsanul orcidid: 0000-0002-4408-6104 surname: Haq fullname: Haq, Ahsanul organization: Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh – sequence: 3 givenname: Mohib Ullah orcidid: 0000-0003-1021-4435 surname: Khondoker fullname: Khondoker, Mohib Ullah organization: Department of Community Medicine, Gonoshasthaya Samaj Vittik Medical College, Savar, Dhaka, Bangladesh – sequence: 4 givenname: Tamanna orcidid: 0000-0001-9139-6095 surname: Ali fullname: Ali, Tamanna organization: Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh – sequence: 5 givenname: Firoz orcidid: 0000-0002-6218-201X surname: Ahmed, Md fullname: Ahmed, Md, Firoz organization: Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh – sequence: 6 givenname: Shahad Saif orcidid: 0000-0003-4724-0645 surname: Khandker fullname: Khandker, Shahad Saif organization: Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka, Bangladesh – sequence: 7 givenname: Irfan orcidid: 0000-0001-9653-5656 surname: Jawad fullname: Jawad, Irfan organization: Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh – sequence: 8 givenname: Rubel orcidid: 0000-0003-3805-7101 surname: Hossain fullname: Hossain, Rubel organization: Department of Microbiology, Gono Bishwabidyalay, Savar, Dhaka, Bangladesh – sequence: 9 givenname: Sohel orcidid: 0000-0001-5985-4578 surname: Ahmed fullname: Ahmed, Sohel organization: Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka, Bangladesh – sequence: 10 givenname: Sabita Rezwana orcidid: 0000-0002-0543-1905 surname: Rahman fullname: Rahman, Sabita Rezwana organization: Department of Microbiology, University of Dhaka, Dhaka, Bangladesh – sequence: 11 givenname: Mamun orcidid: 0000-0002-5075-2783 surname: Mustafi fullname: Mustafi, Mamun organization: Department of Community Medicine, Gonoshasthaya Samaj Vittik Medical College, Savar, Dhaka, Bangladesh – sequence: 12 givenname: Taku orcidid: 0000-0001-5556-8179 surname: Kaitsuka fullname: Kaitsuka, Taku organization: Department of Pharmaceutical Sciences, School of Pharmacy, International University of Health and Welfare, Okawa, Fukuoka, Japan – sequence: 13 givenname: Masayasu orcidid: 0000-0003-2255-3346 surname: Mie fullname: Mie, Masayasu organization: School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Kanagawa, Japan – sequence: 14 givenname: Kazuhito orcidid: 0000-0002-5663-2627 surname: Tomizawa fullname: Tomizawa, Kazuhito organization: Department of Molecular Physiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan – sequence: 15 givenname: Eiry orcidid: 0000-0002-2468-5804 surname: Kobatake fullname: Kobatake, Eiry organization: School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Kanagawa, Japan – sequence: 16 givenname: Mainul orcidid: 0000-0002-6124-7993 surname: Haque fullname: Haque, Mainul organization: The Unit of Pharmacology, Faculty of Medicine and Defence Health Universiti Pertahanan, Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sugai Besi, Kuala Lumpur, Malaysia – sequence: 17 givenname: Nihad orcidid: 0000-0002-4999-4793 surname: Adnan fullname: Adnan, Nihad organization: Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34503369$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kN1OAyEQhYnR2B99BA0vsBUGWJbL2vrTpElv1AtvGhZYi2mhWWhj316MejOTfDlncs6M0HmIwSF0Q8mEkobcUS5rIho-AQJ0QpWUNSNnaEgl51XDlBigUUqfhDCuhLxEA8YFYaxWQ_Q1Ddm30Z5w79I-huRwjjhvHO58nzK2sZDY4en7nAIAPmpjfHDYBzxbvS3mFVXYxHDUW5eMCxnrYPEh-NA5k50tOuuP3h70Nv147nX42Grr0uYKXXQFuuu_PUavjw8vs-dquXpazKbLyggKueJS1Fo1nXSu5O0sa2UjqSQKBCtQWVCMWA6tKlOBZm3dUgmyFDQADcAY3f7e3R_anbPrfe93uj-t_18A3we1XU8 |
CitedBy_id | crossref_primary_10_4236_aid_2023_132023 crossref_primary_10_3390_bioengineering9020072 crossref_primary_10_1038_s41598_023_47611_w crossref_primary_10_3390_vaccines11010051 crossref_primary_10_3390_life12050649 crossref_primary_10_3389_fimmu_2023_1128330 crossref_primary_10_7759_cureus_47683 crossref_primary_10_2174_1568026623666230825094341 crossref_primary_10_3390_vaccines12050482 crossref_primary_10_1007_s12288_023_01716_4 crossref_primary_10_3390_vaccines9121387 crossref_primary_10_7759_cureus_27428 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1080/14760584.2021.1977630 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1744-8395 |
ExternalDocumentID | 34503369 |
Genre | Journal Article |
GeographicLocations | Bangladesh |
GeographicLocations_xml | – name: Bangladesh |
GroupedDBID | --- 0BK 0VX 0YH 29G 3V. 4.4 53G 5GY 7X7 88E 8AO 8C1 8FI 8FJ AAGSP AAHJP AANCX AAOUU ABEIZ ABJNI ABJXJ ABKMU ABLKL ABUWG ABXYU ACFRI ACGFS ACNPW ADBBV ADCVX AECIN AENEX AEOZL AESAV AFKRA AGDLA AGMLL AHMBA AIJEM AIYSM AKBVH ALIPV ALMA_UNASSIGNED_HOLDINGS ALQZU AN0 BENPR BLEHA BNQBC BPHCQ BVXVI CBZEQ CCCUG CCPQU CGR CS3 CUY CVF DDEWX DGYZD DU5 EBS ECM EIF EJD F5P FYUFA GROUPED_DOAJ H13 HMCUK HZ~ IAO IEA IHR ITC KYCEM LJTGL M1P M4Z MV1 NPM O9- OVD P2P PQQKQ PROAC PSQYO RFE RNANH SJN TBQAZ TCNNB TDBHL TEORI TFL TFW TUROJ UKHRP |
ID | FETCH-LOGICAL-c512t-4756a98f7ee369fd3b7871709253f7e9d2930d42b90d492a3b6b1727450c22822 |
IngestDate | Sun Oct 13 09:52:07 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | COVID-19 AZD1222 IgA convalescence seroconversion SARS-COV-2 IgG IgM |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c512t-4756a98f7ee369fd3b7871709253f7e9d2930d42b90d492a3b6b1727450c22822 |
ORCID | 0000-0003-4724-0645 0000-0002-6124-7993 0000-0003-1021-4435 0000-0001-9139-6095 0000-0001-5985-4578 0000-0002-4999-4793 0000-0002-5663-2627 0000-0002-2468-5804 0000-0003-3805-7101 0000-0003-0495-4808 0000-0002-4408-6104 0000-0002-6218-201X 0000-0002-0543-1905 0000-0003-2255-3346 0000-0001-5556-8179 0000-0002-5075-2783 0000-0001-9653-5656 |
OpenAccessLink | https://europepmc.org/articles/pmc8442763?pdf=render |
PMID | 34503369 |
ParticipantIDs | pubmed_primary_34503369 |
PublicationCentury | 2000 |
PublicationDate | 2021-12-02 |
PublicationDateYYYYMMDD | 2021-12-02 |
PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-02 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Expert review of vaccines |
PublicationTitleAlternate | Expert Rev Vaccines |
PublicationYear | 2021 |
SSID | ssj0034957 |
Score | 2.4184685 |
Snippet | Vaccination with the Oxford-AstraZeneca COVID-19 vaccine (AZD1222) initially started in the UK and quickly implemented around the Globe, including Bangladesh.... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1651 |
SubjectTerms | Antibodies, Viral - blood Antibody Formation Bangladesh ChAdOx1 nCoV-19 COVID-19 COVID-19 Vaccines - immunology Humans Immunoglobulin A - blood Immunoglobulin G - blood Immunoglobulin M - blood |
Title | Antibody response to the first dose of AZD1222 vaccine in COVID-19 convalescent and uninfected individuals in Bangladesh |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34503369 |
Volume | 20 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELY6EGgvaPwaGwP5gbcqI3acuHksDDRAGxJq0cTLdI4dNQ9NxpZOG38TfyRnO17CGAh4sSpbTRvfp_P57rs7Ql5kWkiVyTgCZZj1VhURyCJFLDMwwJQBZf2QB4fZ_ly8P0qPRqPvA9bSqlW7xbcb80r-R6o4h3K1WbL_INmrh-IEfkb54ogSxvGvZDyt20o1-nJ86pmuJliSZYVG3Vg33lE__bLH8IAen0Nhw-gu0e_j53d7Ecsd6xy6mk4ukLCqPT_L2KJMIVnLkWZfgW34oc3Z4id3vq2V3A5SYLpf6amJsKxOV1r7YgWfwHTpVE7tfXW6aXEGdU9Q_LCwLUY6tsdBs6jUeI5gvfJbT31G9wyWUPve38FtwZmjgHi9a7yqlUJEaJ6lQ13M4yHm-ECzsswXpv1F5XuOJBPSBnitl4yzXYZWbebjPQMYnCwdDhJhQ7e-QcyfV69V4g5La2RNTqw2PbSeIX_qJ3jRlCFDbBK_vPH_rJO74RnXbjHOmpltkHvdNYROPabuk5GpH5A7vjHp5UNyEZBFA7Jo21BEFnXIohZZtClphyzayZxWNQ3IokNkUUQW7ZFFB8iy3-mR9YjM376Zvd6Puh4dUYGmYhsJmWaQT0ppDL5VqROFJwCTcc7TBCdzjeZkrAVXOY45h0RlytrMuA0FtxTmx-RW3dTmCaGpYpAZaQDPGKGFmcgkgwK4AFHyMo-3yKbfsuMTX4jlOGzm9m9XnpL1Hnw75HaJ72WeoRnZqudOfj8AfVxvEw |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibody+response+to+the+first+dose+of+AZD1222+vaccine+in+COVID-19+convalescent+and+uninfected+individuals+in+Bangladesh&rft.jtitle=Expert+review+of+vaccines&rft.au=Jamiruddin%2C+Raeed&rft.au=Haq%2C+Ahsanul&rft.au=Khondoker%2C+Mohib+Ullah&rft.au=Ali%2C+Tamanna&rft.date=2021-12-02&rft.eissn=1744-8395&rft.volume=20&rft.issue=12&rft.spage=1651&rft_id=info:doi/10.1080%2F14760584.2021.1977630&rft_id=info%3Apmid%2F34503369&rft_id=info%3Apmid%2F34503369&rft.externalDocID=34503369 |